Abstract | BACKGROUND: METHODS: RESULTS: In total, 33 trials involving 2418 individuals were included and analyzed. T790M was significantly less frequent after afatinib treatment (40.2%, 95% confidence interval [CI]: 31.7%-48.7%) than after gefitinib and erlotinib treatments (52.5%, 95% CI: 48.7%-56.3%, p = 0.005). There were no significant differences between Asian and non-Asian patients in the incidence of T790M after gefitinib, erlotinib, and afatinib treatments. Regarding epidermal growth factor receptor pathway-independent resistant mechanisms, the incidences of small cell lung cancer transformation ( osimertinib: 7.9%, 95% CI: 3.6%-12.2%, others: 2.3%, 95% CI: 0.8%-3.8%) and Kirsten rat sarcoma (KRAS) viral oncogene homolog mutation ( osimertinib: 4.6%, 95% CI: 1.5%-7.7%, others: 0.2%, 95% CI: 0.0%-1.7%) were significantly higher following osimertinib treatment than with others. CONCLUSIONS:
|
Authors | Nobuaki Kobayashi, Seigo Katakura, Chisato Kamimaki, Kohei Somekawa, Nobuhiko Fukuda, Katsushi Tanaka, Keisuke Watanabe, Nobuyuki Horita, Yu Hara, Hongmei Piao, Takeshi Kaneko |
Journal | Thoracic cancer
(Thorac Cancer)
Vol. 12
Issue 7
Pg. 1096-1105
(04 2021)
ISSN: 1759-7714 [Electronic] Singapore |
PMID | 33565276
(Publication Type: Journal Article, Meta-Analysis)
|
Copyright | © 2021 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd. |
Chemical References |
- Protein Kinase Inhibitors
|
Topics |
- Carcinoma, Non-Small-Cell Lung
(drug therapy, pathology)
- Humans
- Lung Neoplasms
(drug therapy, pathology)
- Protein Kinase Inhibitors
(pharmacology, therapeutic use)
- Treatment Outcome
|